33,504 Shares in Moderna, Inc. (NASDAQ:MRNA) Purchased by Avanza Fonder AB

Avanza Fonder AB purchased a new stake in Moderna, Inc. (NASDAQ:MRNA) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 33,504 shares of the company’s stock, valued at approximately $1,393,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. State Street Corp increased its holdings in shares of Moderna by 12.1% during the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company’s stock worth $1,125,899,000 after buying an additional 1,823,276 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Moderna by 21.0% in the third quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock valued at $349,166,000 after acquiring an additional 906,114 shares during the last quarter. Two Sigma Advisers LP purchased a new stake in Moderna during the third quarter valued at about $23,825,000. International Assets Investment Management LLC increased its stake in Moderna by 10,687.1% during the third quarter. International Assets Investment Management LLC now owns 319,514 shares of the company’s stock worth $21,353,000 after acquiring an additional 316,552 shares during the last quarter. Finally, Douglas Lane & Associates LLC raised its holdings in shares of Moderna by 62.9% in the 4th quarter. Douglas Lane & Associates LLC now owns 773,804 shares of the company’s stock worth $32,175,000 after purchasing an additional 298,715 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Leerink Partners dropped their target price on shares of Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a research report on Thursday. Piper Sandler reissued an “overweight” rating and issued a $69.00 price objective (down previously from $115.00) on shares of Moderna in a research report on Monday, November 18th. HSBC upgraded shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 target price on the stock in a report on Monday, November 18th. Bank of America reiterated an “underperform” rating and issued a $41.00 price target on shares of Moderna in a report on Tuesday, December 10th. Finally, Wolfe Research started coverage on Moderna in a research note on Friday, November 15th. They set an “underperform” rating and a $40.00 price objective on the stock. Four equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $75.58.

Insider Transactions at Moderna

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the transaction, the insider now owns 19,717 shares in the company, valued at $843,690.43. The trade was a 6.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last three months, insiders have sold 2,664 shares of company stock worth $115,210. 15.20% of the stock is currently owned by insiders.

Moderna Stock Performance

Shares of Moderna stock opened at $34.06 on Friday. The firm has a market cap of $13.11 billion, a PE ratio of -5.85 and a beta of 1.60. Moderna, Inc. has a 1 year low of $31.94 and a 1 year high of $170.47. The firm’s 50-day simple moving average is $40.85 and its 200-day simple moving average is $66.40. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. The company had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. Moderna’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter last year, the business posted ($1.39) EPS. Equities analysts forecast that Moderna, Inc. will post -9.3 earnings per share for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.